| Name | Title | Contact Details |
|---|
Icario is a health action company that frees you to help people live healthier lives by helping you connect with them like they`re human. With over 100 million+ member connections, Icario is a health action platform that unites pioneering technology, data science, and behavioral insights to connect everyone to better health. Our mission is to make the world a healthier place, one person at a time. In 2020, Revel + NovuHealth joined forces to create Icario because we knew we could do better together—creating value by uniting pioneering technology, data science, and behavioral insights to make the world a healthier place, one person at a time. There is an island in the Aegean Sea where people live extremely long lives. They`re happy, too. Families are close. They eat well. They exercise. And they stay connected with each other, and not just by smartphone. This got us thinking. What if we apply what we learn from the Blue Zone island of Ikaria (our namesake), add pioneering technology and exabytes of data, and help healthcare connect better with everyone? We`ll have a lot more healthy, happy people, and that`s a pretty good thing. As an organization, we`re a collaborative team of pioneers, inventors, and systems thinkers. We speak truth, are driven by data, and sweat the details. We`re a friendly and easygoing group, but we work hard because we are mission-driven, we know a better way, and we`re here to make it happen.
CG HEALTHCARE SOLUTIONS is a Toms River, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chancellor Health Trust is a Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Good Shepherd Geriatric Ctr is a Mason City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.